Journal of Clinical Immunology

, Volume 26, Issue 5, pp 430–437 | Cite as

Vasoactive Intestinal Polypeptide Suppressed Experimental Autoimmune Encephalomyelitis by Inhibiting T Helper 1 Responses

  • Haiyan Li
  • Yunhua Mei
  • Ying Wang
  • Lingyun Xu


Vasoactive intestinal peptide (VIP) has been found to act as a potent anti-inflammatory factor through regulating the production of both anti- and pro-inflammatory mediators and promoting Th2-type responses. In this study, we used myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (EAE) model in C57BL/6 mice to investigate the potential effects of VIP on multiple sclerosis. Our results showed that in vivo treatment of EAE-induced mice with VIP had great protective benefit at both clinical and histological levels. Disease suppression was associated with the inhibition of T cells proliferation, shifting of the immune response toward a Th2-type response and influencing the expression of pro-inflammatory cytokines including IFN-γ, IL-6 and IL-2 as well as chemotactic factors such as RANTES. In conclusion, the study provides evidence that VIP had great protective effect on EAE through its inhibition actions on pathogenic T cells and through a specific effect on the Th1 response.


Vasoactive intestinal polypeptide experimental autoimmune encephalomyelitis T helper 1 cells 



The helpful advice of Prof. Jingwu Zang was greatly appreciated. This work was supported in part by Science and Technology Commission of Shanghai Municipality (Project 04DZ14902), Shanghai Rising-Star Program (04QMX1423) and Shanghai Leading Academic Discipline Project (T0206).


  1. 1.
    Said SI, Mutt V: Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217–1218, 1970.PubMedCrossRefGoogle Scholar
  2. 2.
    Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 15:504–511, 1994.PubMedCrossRefGoogle Scholar
  3. 3.
    Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M: Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Des 7:89–111, 2001.PubMedCrossRefGoogle Scholar
  4. 4.
    Pozo D: VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol Med 9:211–217, 2003.PubMedCrossRefGoogle Scholar
  5. 5.
    Delgado M, Pozo D, Ganea D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249–290, 2004.PubMedCrossRefGoogle Scholar
  6. 6.
    Calvo JR, Pozo D, Guerrero JM: Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv Neuroimmunol 6:39–47, 1996.PubMedCrossRefGoogle Scholar
  7. 7.
    Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA: International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265–270, 1998.PubMedGoogle Scholar
  8. 8.
    Delgado M: VIP: A very important peptide in T helper differentiation. Trends Immunol 24:221–224, 2003.PubMedCrossRefGoogle Scholar
  9. 9.
    Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology 124:961–971, 2003.PubMedCrossRefGoogle Scholar
  10. 10.
    Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Usui M: Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 122:1179–1184, 2004.PubMedCrossRefGoogle Scholar
  11. 11.
    Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563–568, 2001.PubMedCrossRefGoogle Scholar
  12. 12.
    Giovannoni G, Hartung HP: The immunopathogenesis of multiple sclerosis and Guillain-Barre syndrome. Curr Opin Neurol 9:165–177, 1996.PubMedCrossRefGoogle Scholar
  13. 13.
    Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579–621, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Steinman L: Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24:511–514, 1999.PubMedCrossRefGoogle Scholar
  15. 15.
    Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J: Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med 75:77–88, 1997.PubMedCrossRefGoogle Scholar
  16. 16.
    Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C: Animal models. Ann Neurol 36(Suppl):S47–S53, 1994.CrossRefGoogle Scholar
  17. 17.
    Teresi S, Boudard F, Bastide M: Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8 T cell proliferation. Immunol Lett 50:105–113, 1996.PubMedCrossRefGoogle Scholar
  18. 18.
    Delgado M, Chorny A, Gonzalez-Rey E, Ganea D: Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol 78:1327–1338, 2005.PubMedCrossRefGoogle Scholar
  19. 19.
    Ersoy E, Kus CN, Sener U, Coker I, Zorlu Y: The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 12:208–211, 2005.PubMedCrossRefGoogle Scholar
  20. 20.
    Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78–84, 2002.PubMedCrossRefGoogle Scholar
  21. 21.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 96:167–181, 1999.PubMedCrossRefGoogle Scholar
  22. 22.
    Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem 274:31930–31940, 1999.PubMedCrossRefGoogle Scholar
  23. 23.
    Delgado M, Leceta J, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 163:3629–3635, 1999.PubMedGoogle Scholar
  24. 24.
    Ranger AM, Das MP, Kuchroo VK, Glimcher LH: B7-2 (CD86) is essential for the development of IL-4-producing T cells. Int Immunol 8:1549–1560, 1996.PubMedCrossRefGoogle Scholar
  25. 25.
    Ganea D, Delgado M: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13:229–237, 2002.PubMedCrossRefGoogle Scholar
  26. 26.
    Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 16:1844–1846, 2002.PubMedGoogle Scholar
  27. 27.
    Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A: IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 28:2178–2187, 1998.PubMedCrossRefGoogle Scholar
  28. 28.
    Ransohoff RM: The chemokine system in neuroinflammation: An update. J Infect Dis 186(Suppl 2):S152–S156, 2002.PubMedCrossRefGoogle Scholar
  29. 29.
    Delgado M, Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167:966–975, 2001.PubMedGoogle Scholar
  30. 30.
    Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, Delgado M: Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: Down-regulation of inflammatory and autoimmune responses. Am J Pathol 168:1179–1188, 2006.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Haiyan Li
    • 1
    • 2
  • Yunhua Mei
    • 1
  • Ying Wang
    • 1
  • Lingyun Xu
    • 1
    • 2
    • 3
  1. 1.Shanghai Institute of ImmunologyShanghai Jiao Tong University Medical SchoolShanghaiP. R. China
  2. 2.Institute of Health SciencesShanghai Jiao Tong University/Shanghai Institutes for Biological Sciences, Chinese Academy of SciencesShanghaiP. R. China
  3. 3.Shanghai Institute of ImmunologyShanghai Jiao Tong University Medical SchoolShanghaiP. R. China

Personalised recommendations